RFA-EY-25-001 (Historical Reference): BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21)

RFA-EY-25-001 (Historical Reference): BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21)

Historical status

The National Institutes of Health (NIH) notice for RFA-EY-25-001 has expired. The official NIH Guide page says the notice is expired and directs applicants to check the NIH Guide for active opportunities and notices. The final new-application deadline listed by the notice was June 15, 2026, with applications due by 5:00 p.m. local time of the applicant organization. The notice’s expiration date was June 16, 2026. This page keeps the real closed-cycle deadline in its metadata and is a historical reference, not an open call.

The verified official notice does not list a successor R21 cycle or a replacement deadline. The two dates in the notice’s application table were part of this completed announcement: June 17, 2025 and June 15, 2026. Readers should not treat either date as a future submission opportunity, and they should not assume that NIH will reissue the program on the same schedule. Check the active NIH Guide and the relevant NIH institute or center before preparing a new application.

Key details

What the completed NOFO was designed to fund

The NOFO sought unique and innovative recording and/or modulation technologies in the earliest stage of development, including new and untested ideas at the initial conceptualization stage. Some proposed technologies could aim to increase recording or modulation capacity by many orders of magnitude. Others could focus on improving precision and selectivity, including cell-type or neurochemical specificity. The notice allowed a broad range of modalities, including acoustic, chemical, electrical, magnetic, and optical approaches, as well as genetic tools.

The intended scientific setting was neural activity in the central nervous system. The proposed approach could be invasive or non-invasive, but it needed a credible path toward eventual use in humans or behaving animals. The notice was concerned with major barriers to recording and manipulating neural circuits, not simply with applying a familiar measurement to a routine biological question. It also encouraged applications from fields that do not always sit inside traditional neuroscience departments.

Examples of a responsive project could include a new physical principle for recording neural signals, a new method for precise manipulation, a combination of existing technologies that produces a distinct capability, or a theoretical design that addresses a known limitation in spatial extent, resolution, or temporal dynamics. The notice also contemplated early-stage work using calculations, simulations, computational models, mathematical techniques, phantoms, prototypes, in-vitro systems, or other bench-top models. Those tools were acceptable when they were used to test underlying assumptions and show feasibility for a future biological application.

This was an R21 Exploratory/Developmental Research Grant. NIH’s R21 review language states that an application need not have extensive background material or preliminary information. Preliminary data were not required, although investigators could include them when available. That distinction did not remove the need for a rigorous rationale: the application still had to explain the scientific problem, the physical or biological basis of the proposed approach, the feasibility tests, and the limitations that would be measured.

The BRAIN Initiative context was the development of tools that can reveal how individual cells and neural circuits interact across time and space. A strong historical fit therefore needed to show how a proposed recording or modulation method could improve what researchers can observe or control. A project that only promised incremental refinement, or one centered on a clinical trial, would not match this notice.

Funding details

NIH intended to fund an estimated 10 awards per fiscal year, corresponding to $3-$4 million in new awards per year. Those figures describe the program’s anticipated award volume, not a guaranteed amount for any individual applicant. The application budget could not exceed $400,000 in total direct costs over a maximum three-year funding period, and no more than $200,000 in direct costs could be requested in any single year. The scope of the proposed work was supposed to determine the project period, subject to the three-year maximum.

The budget ceiling was not a flat award amount. A team had to request only the costs necessary for the proposed work and explain how those costs supported the research plan. A project could use the R21 structure for a tightly bounded technology-development effort, but the three-year cap made a large, mature engineering program a poor fit. The notice described a grant mechanism, not a cooperative agreement, and clinical trials were not allowed.

The official review-and-award table paired the June 17, 2025 new-application date with scientific merit review in November 2025, advisory council review in January 2026, and an earliest start date in April 2026. It paired the June 15, 2026 new-application date with review in November 2026, council consideration in January 2027, and an earliest start date in April 2027. These are historical schedule entries from the expired notice, not evidence of an open or rolling program.

Eligibility for the completed cycle

The notice listed a broad set of eligible organizations. They included public and private institutions of higher education; nonprofits with or without 501(c)(3) status; small businesses and other for-profit organizations; state, county, city or township, and special district governments; federally recognized and other tribal governments; eligible federal agencies; U.S. territories or possessions; independent school districts; public housing authorities; Native American tribal organizations; faith-based or community-based organizations; and regional organizations.

Non-domestic entities, including foreign organizations, were eligible to apply. Non-domestic components of U.S. organizations were also eligible, and foreign components as defined in the NIH Grants Policy Statement were allowed. The notice encouraged applications from any qualified individual, naming chemists, physicists, engineers, theoreticians, materials scientists, and others from fields not typically involved with neuroscience research. The announcement did not impose a special PI career-stage restriction in the eligibility section.

Eligibility did not mean that an individual could submit without an institutional application structure. The applicant organization had to have the registrations required for NIH electronic submission, and the notice stressed that registrations needed to be in place by the time of submission:

1. The organization needed an active SAM registration and unique organization identifier.
2. The organization needed Grants.gov registration and access to the application system.
3. The organization needed an eRA Commons account structure with at least one Signing Official and one Program Director/Principal Investigator account.
4. The PI and organization had to resolve registration and submission issues before the applicable deadline.

The official notice warned that late registration was not a substitute for timely submission. Because the cycle is closed, these requirements are retained only to describe how the completed announcement worked; they should be checked again against any future NIH notice before use.

Application process for the closed cycle

The application package specific to the NOFO had to be accessed through ASSIST, Grants.gov Workspace, or an institutional system-to-system solution. Applicants had to follow the NIH Research (R) Instructions in the How to Apply - Application Guide except where the NOFO supplied different instructions. NIH stated that conformance with the application guide and the NOFO was strictly enforced; applications that did not comply could be delayed or not accepted for review.

The submission needed the standard electronic federal forms and the program-specific research material. The Research Strategy was especially important for this notice. It needed to identify, where appropriate, the physical principles that the technology would exploit and explain why those principles could enable a substantial improvement in neural recording or modulation for eventual use in humans or behaving animals. It also needed to explain how calculations, simulations, computational models, mathematical methods, or bench-top tests would demonstrate feasibility and expose theoretical limits.

The application had to follow the Research Plan instructions and page limits in the current NIH application guide. The notice also required the appropriate cover-page, site-location, other-project-information, senior/key-person, budget, and subaward forms. Applicants needed a coherent budget and period justification tied to the proposed work rather than a generic request for the full cap.

The notice required the Resource Sharing Plan instructions in the application guide. When the proposed research generated scientific data, the NIH Data Management and Sharing Policy and the approved plan would govern data management and sharing. BRAIN-related data-sharing expectations could matter to the project, but they did not replace the formal application-guide requirements. Teams also had to address human subjects, vertebrate animals, biohazards, or other compliance sections when those features were relevant.

The submission route was electronic. A completed application had to be submitted through the selected NIH-compatible system and tracked through the relevant federal and NIH systems. Paper submission was not the route described by the NOFO. The due time was 5:00 p.m. in the applicant organization’s local time, and NIH encouraged early submission so errors found during electronic validation could be corrected before the deadline.

Scientific fit and review considerations

The R21 mechanism placed particular weight on the conceptual framework, innovation, and potential to advance biomedical or biobehavioral research. Reviewers still considered the rationale, scientific background, rigor, feasibility, investigator, and environment. A proposal could be early and ambitious without being vague: it needed tests that could show whether the central idea worked, identify failure conditions, and distinguish a real technical advance from an attractive but unsupported claim.

Good alignment would have connected a defined barrier to a new recording or modulation principle, a measurable feasibility test, and a plausible path to later work in an animal model or human-compatible setting. A simulation-only project could fit if the calculations addressed the physical limits of the proposed approach. A prototype or phantom project could fit if it tested the assumptions that would matter for later biological use. Conversely, a mature commercial product, a routine incremental improvement, a project unrelated to CNS recording or modulation, or a clinical trial would not match the notice’s central purpose.

The announcement’s scientific scope also left room for interdisciplinary teams. A qualified investigator did not need to come from a neuroscience department if the application made the connection to neural recording or modulation clear. Physics, chemistry, materials science, electrical engineering, optics, computation, and related expertise could be relevant. Interdisciplinarity by itself was not enough; every discipline included in the team needed a defined role in the feasibility argument.

What to do now

There is no open submission route for RFA-EY-25-001. The deadline and expiration date have passed, and the verified official notice does not announce another R21 round. Researchers should not submit against the old number, treat the deadline as rolling, or reuse the historical application instructions without checking a new NIH notice.

The useful next step is to monitor the active NIH Guide and the BRAIN Initiative pages for a new notice. A future announcement could change the participating institutes, scientific scope, budget, application types, review criteria, forms, or deadline. It could also replace this R21 with a related mechanism. The old notice’s companion opportunities were RFA-NS-24-004 and RFA-NS-24-005, but those identifiers are not a substitute for a current announcement and should be checked separately before use.

For archival planning, a team studying the same problem should preserve the core questions that made the closed notice distinctive: what neural signal or circuit activity must be measured or controlled, what current physical or biological limitation blocks that task, what new principle could remove the limitation, and what early test would distinguish feasibility from speculation. Those questions can guide a future concept paper, but they do not establish eligibility for a later NIH competition.

The official historical notice remains the controlling source for the completed cycle. Use it to understand the archived scope, funding ceiling, eligible organizations, and submission systems, then verify every requirement against the next official NIH announcement before investing in a new application.

Frequently asked questions

Can I still apply?

No. The final new-application deadline was June 15, 2026, and the notice expired June 16, 2026.

Is there a new deadline?

No successor R21 deadline is listed on the verified official notice. Check the active NIH Guide for any later reissue or related announcement.

What was the award ceiling?

Application budgets could not exceed $400,000 in total direct costs over a maximum three-year period, and no more than $200,000 in direct costs could be requested in a single year. NIH intended about 10 awards per fiscal year totaling $3-$4 million in new awards per year.

Who was eligible?

The notice listed many eligible organization types, including higher education institutions, nonprofits, businesses, governments, tribal organizations, federal agencies, U.S. territories, and regional or community organizations. Foreign organizations and non-domestic components of U.S. organizations were eligible under the stated rules. Any future cycle must be checked independently.

Were clinical trials allowed?

No. The notice accepted only applications that did not propose clinical trials.

Did applicants need preliminary data?

No. The R21 review language said preliminary data were not required, although they could be included if available. The application still needed a credible scientific rationale and feasibility plan.

How was an application submitted?

The package had to be accessed through ASSIST, Grants.gov Workspace, or an institutional system-to-system solution. Applicants had to follow the NIH Research (R) Instructions and the specific NOFO instructions. The completed round was not a paper-application process.

Is this page an active listing?

No. It is a historical reference for an expired notice. The official NIH page is the final authority for the completed cycle; use the active NIH Guide and any new official notice for current opportunities.